29,696 Teva Pharmaceutical Industries Ltd. $TEVA Shares Purchased by Jefferies Financial Group Inc.

Jefferies Financial Group Inc. grew its stake in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 65.5% during the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 75,000 shares of the company’s stock after purchasing an additional 29,696 shares during the quarter. Jefferies Financial Group Inc.’s holdings in Teva Pharmaceutical Industries were worth $2,970,000 at the end of the most recent reporting period.

Several other hedge funds also recently modified their holdings of TEVA. Parallel Advisors LLC grew its holdings in Teva Pharmaceutical Industries by 8.7% during the third quarter. Parallel Advisors LLC now owns 4,626 shares of the company’s stock worth $183,000 after buying an additional 370 shares in the last quarter. Envestnet Portfolio Solutions Inc. lifted its stake in Teva Pharmaceutical Industries by 7.1% during the 2nd quarter. Envestnet Portfolio Solutions Inc. now owns 7,311 shares of the company’s stock valued at $248,000 after acquiring an additional 483 shares in the last quarter. First Trust Advisors LP lifted its stake in Teva Pharmaceutical Industries by 5.9% during the 1st quarter. First Trust Advisors LP now owns 9,619 shares of the company’s stock valued at $290,000 after acquiring an additional 539 shares in the last quarter. EverSource Wealth Advisors LLC lifted its stake in Teva Pharmaceutical Industries by 64.0% during the 1st quarter. EverSource Wealth Advisors LLC now owns 1,658 shares of the company’s stock valued at $50,000 after acquiring an additional 647 shares in the last quarter. Finally, Victrix Investment Advisors boosted its holdings in Teva Pharmaceutical Industries by 9.5% during the 2nd quarter. Victrix Investment Advisors now owns 7,850 shares of the company’s stock worth $266,000 after acquiring an additional 681 shares during the last quarter. Hedge funds and other institutional investors own 54.05% of the company’s stock.

Teva Pharmaceutical Industries Stock Up 0.7%

Shares of NYSE:TEVA opened at $43.52 on Friday. The company has a market capitalization of $50.72 billion, a PE ratio of 101.22, a price-to-earnings-growth ratio of 4.05 and a beta of 0.97. The company has a debt-to-equity ratio of 1.59, a current ratio of 0.95 and a quick ratio of 0.74. The business has a fifty day moving average price of $40.00 and a two-hundred day moving average price of $35.01. Teva Pharmaceutical Industries Ltd. has a 1 year low of $24.01 and a 1 year high of $44.31.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its earnings results on Tuesday, November 3rd. The company reported $0.86 EPS for the quarter, topping analysts’ consensus estimates of $0.72 by $0.14. The company had revenue of $4.39 billion for the quarter, compared to analysts’ expectations of $4.23 billion. Teva Pharmaceutical Industries had a return on equity of 33.20% and a net margin of 2.94%. The business’s revenue for the quarter was down 1.9% compared to the same quarter last year. During the same period in the previous year, the business posted $0.78 EPS. Analysts forecast that Teva Pharmaceutical Industries Ltd. will post 1.98 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on TEVA. UBS Group upped their target price on shares of Teva Pharmaceutical Industries from $42.00 to $48.00 and gave the stock a “buy” rating in a research note on Friday, September 4th. JPMorgan Chase & Co. raised their price target on shares of Teva Pharmaceutical Industries from $40.00 to $50.00 and gave the company an “overweight” rating in a research report on Monday, October 12th. Oppenheimer boosted their price target on shares of Teva Pharmaceutical Industries from $50.00 to $52.00 and gave the stock an “outperform” rating in a report on Friday, October 9th. Leerink Partners upped their price objective on shares of Teva Pharmaceutical Industries from $45.00 to $52.00 and gave the stock an “outperform” rating in a research report on Thursday, November 5th. Finally, Barclays increased their price objective on shares of Teva Pharmaceutical Industries from $42.00 to $47.00 and gave the company an “overweight” rating in a research note on Thursday, October 15th. Thirteen analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $48.15.

Insiders Place Their Bets

In other news, insider Brian Savage sold 7,342 shares of the stock in a transaction that occurred on Friday, September 18th. The shares were sold at an average price of $38.85, for a total transaction of $285,236.70. Following the completion of the transaction, the insider directly owned 8,500 shares of the company’s stock, valued at $330,225. This represents a 46.35% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Richard D. Francis sold 250,000 shares of the firm’s stock in a transaction that occurred on Tuesday, November 10th. The stock was sold at an average price of $42.24, for a total transaction of $10,560,000.00. Following the sale, the chief executive officer owned 927,529 shares of the company’s stock, valued at approximately $39,178,824.96. The trade was a 21.23% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders have sold 715,945 shares of company stock valued at $29,061,351. Company insiders own 0.54% of the company’s stock.

Teva Pharmaceutical Industries News Summary

Investors following TEVA have been watching these news items:

• Positive Sentiment: At its R&D Day, Teva outlined a goal of generating $6–7 billion in innovative-medicines revenue by 2030 and shared pipeline updates, including potential first-in-class treatments for Tourette syndrome, celiac disease and intestinal scarring. The growth plan and pipeline progress could strengthen the investment case, though they remain forward-looking goals. R&D Day announcement
• Positive Sentiment: Piper Sandler raised its price target to $56 from $44 and reiterated an Overweight rating, signaling confidence in further upside. Piper Sandler analyst ratings
• Neutral Sentiment: Healthcare stocks broadly declined Wednesday afternoon, a sector headwind that may have affected trading but does not reflect Teva-specific fundamentals. Healthcare sector update

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries is a global pharmaceutical company that develops, manufactures and markets generic medicines, specialty medicines and biosimilars. Its portfolio spans treatments for conditions including neurological disorders, respiratory diseases and cancer, alongside a broad range of generic medicines across therapeutic areas. Founded in Jerusalem in 1901, Teva has grown from a regional pharmaceutical business into an international company. It serves patients and healthcare providers in markets around the world, including North America, Europe and other regions.